First patient dosed in Enanta’s Phase IIb/III trial for RSV

​

Enanta Pharmaceuticals has dosed the first patient in its Phase IIb/III RESOLVE trial assessing zelicapavir in high-risk adult outpatients diagnosed with RSV infection.

The post First patient dosed in Enanta’s Phase IIb/III trial for RSV appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.